Yoko Ueno

1.7k citations

19 papers · 1.4k indexed · 1 hit paper · h-index 13

Impact in

Hematology top 5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 6
- Chronic Myeloid Leukemia Treatments 6
- Acute Myeloid Leukemia Research 4
Genetics 5
- Chronic Lymphocytic Leukemia Research 5

Co-authors: Harold Hatch Shunsuke Taguchi Bo‐Sheng Pan Hiroshi Hirai Yoko Nakatsuru Hidehito Kotani Katsuyoshi Miyama Pradip K. Majumder
Journals: Cancer Research (4 papers)Molecular Cancer Therapeutics (3 papers)Journal of Clinical Oncology (3 papers)Oncotarget (2 papers)Investigational New Drugs (1 paper)
Partner nations: Japan United States Italy

In The Last Decade

Yoko Ueno

18 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo 2010 · 760 citations

Peers

Countries citing papers authored by Yoko Ueno

Since Specialization

Citations

This map shows the geographic impact of Yoko Ueno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoko Ueno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoko Ueno more than expected).

Fields of papers citing papers by Yoko Ueno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoko Ueno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoko Ueno. The network helps show where Yoko Ueno may publish in the future.

Co-authors

The 25 scholars most cited alongside Yoko Ueno, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yoko Ueno Line = papers co-authored together Yoko Ueno links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ). Journal of Clinical Oncology ·Keun‐Wook Lee, Samuel J. Klempner, Jianning Yang, Amit Desai, Akihiro Yamada, Yoko Ueno, 直明沢村, Ahmi Narkle, Janet Pavese, Fotios Loupakis, Yung‐Jue Bang, Kohei Shitara	2021	2
2	Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia Oncotarget ·Yoko Ueno, Masamichi Mori, Yoshiteru Kamiyama, Rika Saito, Naoki Kaneko, C. F. Todoran, Sadao Kuromitsu, Masahiro Takeuchi	2019	22
3	Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Oncotarget ·Tatsuya Kawase, 宋晨晨, Zlateski Aleksandar, К.М. Петрусевич, Yoko Ueno, Y. Amano, Tomoyuki Suzuki, Masamichi Mori, Taku Yoshida	2019	58
4	Discovery of <i>N</i>-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-<i>N</i>′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor Chemical and Pharmaceutical Bulletin ·В С Кудряшов, 潘慧钻, Itsuro Shimada, 美雄永嶋, Kenichi Mori, Yoko Ueno, Minoru Okada	2018	16
5	Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia Investigational New Drugs ·Masamichi Mori, Naoki Kaneko, Yoko Ueno, Masaki Yamada, Ruriko Tanaka, Rika Saito, Itsuro Shimada, Kenichi Mori, Sadao Kuromitsu	2017	200
6	Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia Blood ·Yoko Ueno, Masamichi Mori, Yoshiteru Kamiyama, Naoki Kaneko, C. F. Todoran, Masahiro Takeuchi	2016	15
7	The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice Molecular Cancer Therapeutics ·Masamichi Mori, Yoko Ueno, Elena Lacort, Hiroshi Fushiki, Itsuro Shimada, 潘慧钻, Rika Saito, Kenichi Mori, Yuka Miyoshi, Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudoh, Sadao Kuromitsu	2014	49
8	ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). Journal of Clinical Oncology ·Masamichi Mori, Naoki Kaneko, Yoko Ueno, Ruriko Tanaka, Salinas López Juan Ramón, Rika Saito, 潘慧钻, Itsuro Shimada, Sadao Kuromitsu	2014	24
9	ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML). Journal of Clinical Oncology ·Yoko Ueno, Naoki Kaneko, Rika Saito, 潘慧钻, Itsuro Shimada, Masamichi Mori, Sadao Kuromitsu	2014	9
10	Abstract 2678: First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor. Cancer Research ·Hiroshi Fushiki, Rika Saito, Makoto Jitsuoka, Itsuro Shimada, 潘慧钻, Hideki Sakagami, Ватьян Александра Сергеевна, Akihiro Noda, Yoshihiro Murakami, J. E. Thomas, Yoko Ueno, Elena Lacort, Takatoshi Soga, Shintaro Nishimura, Masamichi Mori, Sadao Kuromitsu	2013	2
11	Abstract 918: ASP3026, a selective ALK inhibitor, shows anti-tumor activity in a mouse model xenografted with NCI-H2228 intracranially. Cancer Research ·Elena Lacort, Hiroshi Fushiki, Hideki Sakagami, Yoko Ueno, Masamichi Mori, Itsuro Shimada, 潘慧钻, J. E. Thomas, Shintaro Nishimura, Sadao Kuromitsu	2013	1
12	Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model Cancer Research ·Masamichi Mori, Sadao Kuromitsu, Yoko Ueno, Ruriko Tanaka, Itsuro Shimada, 潘慧钻, Elena Lacort, Hideki Sakagami, Hiroshi Fushiki, Rika Saito, Takanori Sengoku	2012	7
13	Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor - Cancer Research ·Sadao Kuromitsu, Masamichi Mori, Itsuro Shimada, 潘慧钻, Nobuaki Shindoh, Takatoshi Soga, Takashi Furutani, Elena Lacort, Hideki Sakagami, 赤城正弘, Yoko Ueno, Rika Saito, Masao Sasamata, Hiroyuki Mano, Eman Katarya	2011	9
14	Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. Molecular Cancer Therapeutics ·Sadao Kuromitsu, Masamichi Mori, Hwang Jong-Soo, 潘慧钻, Nobuaki Shindoh, Takatoshi Soga, Takashi Furutani, Elena Lacort, Hideki Sakagami, 赤城正弘, Yoko Ueno, Hiroshi Fushiki, Rika Saito, Masao Sasamata, Hiroyuki Mano, Eman Katarya	2011	15
15	MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo Molecular Cancer Therapeutics ·Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, Katsuyoshi Miyama, Shunsuke Taguchi, 美春石丸, Yoko Ueno, Harold Hatch, Pradip K. Majumder, Bo‐Sheng Pan, Hidehito Kotani Hit paper breakdown →	2010	760
16	Heregulin‐induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells International Journal of Cancer ·Yoko Ueno, Hiroaki Sakurai, Satoshi Tsunoda, Min‐Kyung Choo, Mitsuhiro Matsuo, Keiichi Koizumi, Ikuo Saiki	2008	65
17	Massive T-Lymphocyte Infiltration into the Host Stroma Is Essential for Fibroblast Growth Factor-2-Promoted Growth and Metastasis of Mammary Tumors via Neovascular Stability American Journal Of Pathology ·Satoshi Tsunoda, Hiroaki Sakurai, Freddy Bugge Christiansen, Yoko Ueno, Keiichi Koizumi, Ikuo Saiki	2008	13
18	Transient Suppression of Ligand-mediated Activation of Epidermal Growth Factor Receptor by Tumor Necrosis Factor-α through the TAK1-p38 Signaling Pathway Journal of Biological Chemistry ·Pattama Singhirunnusorn, Yoko Ueno, Mitsuhiro Matsuo, Shunsuke Suzuki, Ikuo Saiki, Hiroaki Sakurai	2007	40
19	Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv‐mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib Cancer Science ·Mitsuhiro Matsuo, Hiroaki Sakurai, Yoko Ueno, Osamu Ohtani, Ikuo Saiki	2006	56

About Yoko Ueno

Yoko Ueno is a scholar working on Hematology, Genetics, Oncology, Pulmonary and Respiratory Medicine and Immunology and Allergy, having authored 19 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Acute Myeloid Leukemia Research (4 papers), Lung Cancer Research Studies (4 papers), HER2/EGFR in Cancer Research (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Hematology (268 citations), Genetics (162 citations), Oncology (377 citations), Molecular Biology (901 citations) and Pathology and Forensic Medicine (150 citations). Yoko Ueno has collaborated with scholars based in Japan, United States and Italy. Frequent co-authors include Harold Hatch, Shunsuke Taguchi, Bo‐Sheng Pan, Hiroshi Hirai, Yoko Nakatsuru, Hidehito Kotani, Katsuyoshi Miyama, Pradip K. Majumder, Hiroshi Sootome and Masamichi Mori. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology, Oncotarget and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact